​R21/Matrix-M Malaria Vaccines

On 20th May, 2024, Pune-based Serum Institute of India (SII) shipped its first batch of the R21/Matrix-M malaria vaccine to Africa.

What is R21/Matrix-M?

  • The R21//Matrix-M vaccine is the second malaria vaccine to be authorized for use in children in malaria-endemic regions, following the RTS, S/AS01 vaccine, which gained WHO recommendation in 2021.
  • The vaccine has been developed through collaboration between the Jenner Institute at Oxford University and the Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology.
  • R21/Matrix-M vaccine received WHO recommendation for use in children in October, 2023, followed by the announcement of its high efficacy of its Phase ....
Do You Want to Read More?
Subscribe Now

To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.